NemaGen Discoveries Receives Seed Funding
Mark Siracusa
NemaGen Discoveries, Inc., an early-stage therapeutics company and Rutgers University spinout, is working to alleviate two chronic health conditions that impact over 24 million people in the United States: asthma and allergic disease (https://acaai.org/news/facts-statistics/allergies). The company’s hopes of doing so are being bolstered by significant seed funding received from the Foundation Venture Capital Group (FVCG), an affiliate of the New Jersey Health Foundation (NJHF).